ratutrelvir
·Code: TRX01
ratutrelvir: developed by 1 company · 1 clinical trial tracked.
ratutrelvir evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ratutrelvir to TRAW; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ratutrelvir → TRAW affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| TRAWS PHARMA, INC. (TRAW) | Phase 2 |
Clinical Trials (1)
A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19
Primary endpoint: Safety based on adverse events incidence
InterventionalRandomizedopen90 targetStarted 2025-09Completion 2026-0315 sites · Australia, South Korea, Taiwan, UzbekistanTraws Pharma, Inc.
Frequently asked questions
Who is developing ratutrelvir?
ratutrelvir is being developed by TRAWS PHARMA, INC..
How many clinical trials involve ratutrelvir?
BioSniper tracks 1 clinical trial involving ratutrelvir.